Plain-English translation of NCT06483100 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach for people with multiple myeloma who have recently had a stem cell transplant. You would receive a medication called elranatamab as maintenance therapy, and your treatment plan would be guided by special blood tests that measure whether any cancer cells remain in your body. The goal is to create a personalized plan—continuing treatment when needed, or pausing it when your cancer appears to be in remission.
Even after successful stem cell transplant, some patients still have trace amounts of cancer cells that can grow back. This trial is testing whether using blood markers to guide treatment decisions could help keep cancer under control longer and avoid unnecessary treatment when it's safe to pause.
You likely qualify if…
You likely don't qualify if…
You would receive at least 12 months of maintenance treatment with the medication. Every 6 months, you would have a special blood test to check if any cancer cells remain. If two tests in a row show no cancer cells, you can stop the medication and move to a monitoring schedule with check-ups every 3 months. If cancer cells appear again, you would restart treatment. Your total time in the study could be up to 3 years for treatment and follow-up combined.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States